Boston Scientific (NYSE:BSX) Price Target Cut to $94.00 by Analysts at Citigroup

Boston Scientific (NYSE:BSX) had its price target cut by Citigroup from $102.00 to $94.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

Several other research firms have also recently issued reports on BSX. Needham & Company LLC lowered their target price on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Morgan Stanley decreased their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Royal Bank Of Canada lowered their price objective on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Mizuho dropped their target price on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, JPMorgan Chase & Co. cut their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $108.00.

Boston Scientific Stock Down 0.5%

Boston Scientific stock opened at $69.58 on Wednesday. Boston Scientific has a 12 month low of $68.19 and a 12 month high of $109.50. The stock has a fifty day simple moving average of $83.51 and a two-hundred day simple moving average of $93.81. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm has a market cap of $103.24 billion, a price-to-earnings ratio of 35.86, a PEG ratio of 0.98 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the prior year, the company posted $0.70 earnings per share. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts predict that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors have recently bought and sold shares of BSX. Steph & Co. purchased a new position in shares of Boston Scientific in the third quarter valued at about $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific during the third quarter worth about $25,000. Murphy & Mullick Capital Management Corp grew its position in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new stake in Boston Scientific during the 2nd quarter valued at approximately $26,000. Finally, Swiss RE Ltd. purchased a new position in Boston Scientific in the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup cut its price target on BSX from $102 to $94 but kept a “buy” rating — signaling the firm still sees meaningful upside even after lowering near-term expectations. This preserves analyst support that can limit downside pressure. Citigroup Lowers PT
• Neutral Sentiment: Unusually large volume of put-option purchases was reported, indicating traders are hedging or speculating on further downside; this raises short‑term volatility but can reflect transient positioning rather than a change in fundamentals. Put Options Flow
• Negative Sentiment: Multiple law firms have filed or announced investigations and class actions against Boston Scientific covering purchases between July 23, 2025 and Feb 3, 2026; plaintiffs allege securities-law violations. A growing wave of litigation increases legal risk, potential discovery costs, and an overhang that often weighs on shares. Bronstein Class Action
• Negative Sentiment: Numerous plaintiff firms (including Rosen, Faruqi, RGRD, Bragar Eagel & Squire, and others) are soliciting lead-plaintiff motions and reminding shareholders of the May 4, 2026 deadline — amplifying publicity and the probability of consolidated litigation. That sustained media/legal attention typically pressures near-term sentiment and can increase legal-cost uncertainty. Deadline Reminder

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.